FutureMeds will move its Regional Headquarters and FutureMeds Wrocław Dedicated Research Site to a new modern Class A office building in the heart of Wrocław, Poland, in the 3rd quarter of 2023.
FutureMeds' Regional HQ teams and Wrocław’s Dedicated Research Site team will occupy a total of 1,100 square metres of a new, modern Class A office building located in the centre of Wrocław at John Paul II Square (Plac Jana Pawła II) by the end of 2023.
Poland: a growing clinical trial powerhouse
Establishing a Regional HQ in Poland is central to FutureMeds’ growth plans, and our teams are committed to strengthening our presence in the country and the Central and Eastern European region, creating more employment opportunities, developing our Dedicated Research Site network and increasing the valuable scientific contribution both locally and globally.
Compared to the more established markets, Poland and Central and Eastern Europe offer higher site productivity, lower costs & trial set-up costs and a solid quality reputation. A strong presence in Poland will enable FutureMeds to deliver greater value to clients and help a growing European patient population gain access to cutting-edge treatments.
Poland has been propelled into an innovative biopharmaceutical industry clinical trials (iBPCTs) powerhouse status by the country’s centralised healthcare system, motivated investigators, large patient population and comparatively low costs.
According to Industry Clinical Trials in Poland 2021 report, Poland ranked 11th globally in terms of iBPCT market share in 2019. During the 2014-2019 period, posted the 5th largest iBPCT market share gain globally, behind China, Spain, South Korea and Taiwan, which economic value of iBPCTs represented more than USD 1.3 billion.
FutureMeds’ new, modern Regional HQ
FutureMeds’ new Regional HQ will be situated on the first floor in a modern 600-square-metre office which will bring together currently distributed key functions and will be designed and equipped with the latest technology and ergonomic furniture to facilitate strong collaboration and effective communication among team members across departments.
“To further support FutureMeds’ growth, deliver greater value to our clients across the globe, and provide patients, clients, employees and partners with a modern, comfortable and safe place to accelerate medical science, we will move our regional HQ into a Class A office building. Having key teams working together will help us deliver the latest drugs and therapies to those who need them faster, regardless of where they are. In addition, we believe FutureMeds’ new regional headquarters will inspire further projects in Poland and abroad.”
- Dr Radosław Janiak, CEO of FutureMeds
FutureMeds Wrocław’s new home
On the ground floor of the building, FutureMeds Wrocław will move into a new 500-square-metre space, offering patient populations easier access to the latest medical treatments as part of the clinical trial process.
The seven-story Class A office building, where the Wrocław Dedicated Research Site and the FutureMeds headquarters will be located, will have an internationally recognised Excellent BREEAM certificate rating and the WELL Health-Safety certificate, demonstrating the quality, performance, safety and sustainability credentials of the new space.
The additional advantages of the building are its excellent location and easy access by car and public transport.
“We are convinced that the new location, along with all its advantages, will give the inhabitants of Wrocław and the surrounding area even faster access to new therapeutic options as part of clinical trials conducted at FutureMeds, as well as the highest standard of medical care offered by the experienced team of the Wrocław Dedicated Research Site”
- Monika Paradyż, Site Director of FutureMeds Wroclaw.
The modern building will house 18,727 square metres of office space, 1,561 square metres of retail space and a three-level underground garage with 311 parking spaces, including places with charging stations for electric vehicles.
About FutureMeds
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.
Comments